Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1287 • ACR Convergence 2021
Association of Limited Health Literacy with Patient-Provider Communication in Systemic Lupus Erythematosus
Ann Barr¹, Catherine Howe², Jennifer Rogers¹, Jayanth Doss¹, Rebecca Sadun¹, Lisa Criscione-Schreiber³, Megan Clowse⁴, Kai Sun³ and Mithu Maheswaranathan³, ¹Duke University, Durham, NC, ²Duke University Hospital, Durham, NC, ³Duke University School of Medicine, Durham, NC, ⁴Duke University, Chapel Hill, NC
Background/Purpose: Low health literacy is common among US adults, including patients with SLE, and is associated with higher disease activity and worse patient-reported outcomes. The…
Abstract Number: 1386 • ACR Convergence 2021
Measurement of TIMP-1 in Pulmonary Vessels May Be a Novel Marker of Reflecting mPAP in CTD-PH
Shusaku Nakashima¹, Kaori Ishikawa¹, Kiyo Ueeda¹, Tomohiro Kameda¹, Hiromi Shimada¹, Risa Wakiya¹, Mansour mai¹, Mikiya Kato¹, Taichi Miyagi², Koichi Sugihara¹, Rina Semba¹, Mao Mizusaki¹ and Hiroaki Dobashi³, ¹Kagawa University, Takamatsu, Japan, ²Kagawa University, Kidagun, Japan, ³Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: CTD is a disease with immune abnormalities which could alter normal cytokine profile. CTD-PH has a different pathogenesis from that of iPAH, and immunosuppressive…
Abstract Number: 1466 • ACR Convergence 2021
Increased Adverse Maternal Postpartum Outcomes in Systemic Lupus Erythematosus Pregnancies Compared to Controls
April Barnado, Janie Hubbard, Sarah Green and Sarah Osmundson, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Studies show increased risks of adverse pregnancy outcomes in SLE patients. Few studies have investigated postpartum outcomes in these patients. Using a large, de-identified…
Abstract Number: 1498 • ACR Convergence 2021
Platelet Secreted LGALS3BP Induces a Pro-inflammatory Phenotype in Systemic Lupus Erythematosus
Hanane EL Bannoudi¹, MacIntosh Cornwell², Elliot Luttrell-Williams², Alexis Engel³, Christina Rolling¹, Peter Izmirly⁴, H. Michael Belmont⁵, Kelly Ruggles², Robert Clancy⁶, Jill Buyon⁵ and Jeffrey Berger², ¹NYU Langone Health, New York, NY, ²New York University, New York, NY, ³NYU Langone Health, New Yok, NY, ⁴New York University School of Medicine, New York, NY, ⁵NYU School of Medicine, New York, NY, ⁶NYU Grossman School of Medicine, New York, NY
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex chronic heterogeneous autoimmune disease, which increases the risk of atherothrombosis. In addition to their well described role…
Abstract Number: 1634 • ACR Convergence 2021
Patient Activation and Health Literacy in the Pediatric to Adult Transition in Juvenile Systemic Lupus Erythematosus: Patient and Health Care Team Perspectives
Ashley Ciosek¹, Una Makris², Justin Kramer³, Tracey Wright⁴ and Nicole Bitencourt⁵, ¹UT Southwestern Medical Center, Dallas, TX, ²UT Southwestern Medical Center, Dallas Veterans Administration, Dallas, TX, ³Texas A&M University, College Station, ⁴UT Southwestern Medical Center, Children's Health, Texas Scottish Rite Hospital for Children, Plano, TX, ⁵Loma Linda University Medical Center, Redlands, CA
Background/Purpose: Advances in treatment of juvenile-onset systemic lupus erythematosus have ensured increased survival such that long-term quality of life and disease management must be considered.…
Abstract Number: 1739 • ACR Convergence 2021
SLE Treatment History and Anifrolumab Efficacy by Baseline Standard Therapies in Patients with SLE from 2 Phase 3 Trials
Susan Manzi¹, Richard Furie², Eric Morand³, Yoshiya Tanaka⁴, Gabriel Abreu⁵, Catharina Lindholm⁵ and Raj Tummala⁶, ¹Allegheny Health Network, Pittsurgh, PA, ²Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, ³Monash University, Melbourne, Australia, ⁴University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁶BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD
Background/Purpose: In the phase 3 TULIP-1 and TULIP-2 trials, anifrolumab, a type I IFN receptor mAb, improved disease activity versus placebo in patients with moderate…
Abstract Number: 1757 • ACR Convergence 2021
Clinical Use of Belimumab for Systemic Lupus Erythematosus in the Setting of Advanced Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: A Case Series
Matthew Snyder¹, Angel Chen¹, Sonali Narain² and Galina Marder², ¹Donald and Barbara Zucker School of Medicine at Hofstra/Northwell at Lenox Hill Hospital Program, New York, NY, ²Northwell Health, Great Neck, NY
Background/Purpose: Belimumab is FDA approved for treatment of SLE and Lupus Nephritis. Patients with an eGFR < 30 ml/min/1.73m2 were excluded from clinical trials, thus…
Abstract Number: 1905 • ACR Convergence 2021
CD11c+ Expression Associates with IFN-λ Responsiveness in Human B Cells with Clinical Implications for SLE
Jennifer Barnas¹, Jennifer Barnard², Cameron Baker², Nida Meednu², Andrew McDavid¹, R. John Looney¹ and Jennifer Anolik², ¹University of Rochester, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY
Background/Purpose: Type I interferon (IFN), namely IFN- α, and B cell aberrations are long recognized in systemic lupus erythematosus (SLE) pathogenesis. Type I IFN receptor…
Abstract Number: 0135 • ACR Convergence 2021
Comparing Rheumatoid Arthritis (RA), Psoriatic Arthritis (PA) and Systemic Lupus Erythematosus (SLE) Total Cost of Care (TCC) in Those with Optimally Managed Depression to Those with Sub-optimally Managed Depression
Joseph Couto¹, Elisea Avalos-Reyes², Amanda McCarthy³, Olga Matlin⁴, Michele Hamburger⁵, Gerard Maher⁶ and Kjel Johnson¹, ¹CVS Health, Lincoln, RI, ²CVS Health, Irving, TX, ³CVS Health, Greensboro, GA, ⁴CVS Health, Northbrook, IL, ⁵Frances Hamburger Institute, Hauppauge, NY, ⁶Frances Hamburger Institute, Hauppaugue, NY
Background/Purpose: Rheumatic diseases (RD) are characterized by systemic signs and symptoms, including articular and extra-articular manifestations. Three common forms of RDs are RA, PsA and…
Abstract Number: 0334 • ACR Convergence 2021
Association Between Systemic Lupus Erythematosus and Myasthenia Gravis: A Population-Based National Study
Sali Merjanah¹, Ann Igoe², David Kaelber³ and Robert Hal Scofield⁴, ¹Boston University, Boston, MA, ²OhioHealth Hospital, Mansfield, OH, ³The MetroHealth System Campus of Case Western Reserve University, Cleveland, OH, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) and myasthenia gravis (MG) are two autoimmune disorders that have a young female preponderance, relapsing-remitting course, and positive antinuclear antibodies.…
Abstract Number: 0353 • ACR Convergence 2021
Soluble Urine ALCAM Reflects Renal Disease Activity in Lupus Nephritis
Dalena Chu¹, Noa Schwartz², Jeanette Ampudia¹, Joel Guthridge³, Judith James³, Jill Buyon⁴, Stephen Connelly¹, Maple Fung⁵, Cherie Ng¹, Chandra Mohan⁶ and Chaim Putterman⁷, ¹Equillium, Inc., La Jolla, CA, ²Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴NYU School of Medicine, New York, NY, ⁵Equillium, Inc., San Diego, CA, ⁶University of Houston, Houston, TX, ⁷Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Lupus nephritis (LN) is a leading cause of morbidity and mortality in systemic lupus erythematosus (SLE) patients. While LN pathogenesis has yet to be…
Abstract Number: 0536 • ACR Convergence 2021
The EIF4 Translational Inhibitor Pateamine a Improves Immunological and Neurological Functions in BXSB.yaa Lupus Mice
Gonzalo Gómez-Hernández¹, Nieves Varela¹, Harini Bagavant², Guillermo Barturen¹, Marta E. Alarcon-Riquelme¹ and Maria Morell¹, ¹GENYO.Center for Genomics and Oncological Research, Granada, Spain, ²Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by loss of tolerance and activation of the immune response. Clinical manifestations are heterogeneous and…
Abstract Number: 0627 • ACR Convergence 2021
Increasing Rates of Standardized Depression Screening in Adolescents and Young Adults with Childhood-Onset Systemic Lupus Erythematosus in a Pediatric Rheumatology Clinic
Emily Datyner¹, Manda Mitchell¹, Brooke Fine¹, Barron Patterson¹, T. Brent Graham¹ and Alaina Davis², ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt Universty Medical Center, Nashville, TN
Background/Purpose: Depression is common and adversely affects health outcomes in adolescents and young adults with childhood-onset systemic lupus erythematous (cSLE).1,2 The aim of our quality…
Abstract Number: 0858 • ACR Convergence 2021
Effect of COVID Infection and COVID Vaccination on SLE Activity, Including Antiphospholipid Antibodies
Michelle Petri¹, Jessica Li² and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD
Background/Purpose: SLE patients may have a particular propensity to some viral infections including zoster and CMV. International studies have suggested that prednisone and rituximab may…
Abstract Number: 0875 • ACR Convergence 2021
Renal Function, Adherence and Low Hydroxychloroquine Dosing Predict HCQ Blood Levels and Lupus Disease Activity
Shivani Garg¹, Karen Hansen², Betty Chewning¹ and Christie Bartels², ¹UW Madison, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Despite weight-based dosing, hydroxychloroquine (HCQ) efficacy varies between individuals. Our meta-analysis based on several studies found that low HCQ levels increased risk of lupus…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].